Skip to main content
Precision Medicine Market Analysis, Size, and Forecast 2025-2029: North America (US and Canada), Europe (France, Germany, Italy, and UK), APAC (China, India, and Japan), South America (Brazil), and Rest of World (ROW)

Precision Medicine Market Analysis, Size, and Forecast 2025-2029:
North America (US and Canada), Europe (France, Germany, Italy, and UK), APAC (China, India, and Japan), South America (Brazil), and Rest of World (ROW)

Published: Jun 2025 222 Pages SKU: IRTNTR75258

Market Overview at a Glance

$78.4 B
Market Opportunity
13%
CAGR
11.3
YoY growth 2024-2025(%)

Precision Medicine Market Size 2025-2029

The precision medicine market size is valued to increase USD 78.4 billion, at a CAGR of 13% from 2024 to 2029. Growing prevalence of chronic diseases will drive the precision medicine market.

Major Market Trends & Insights

  • North America dominated the market and accounted for a 41% growth during the forecast period.
  • By Application - Oncology segment was valued at USD 24.20 billion in 2023
  • By Technology - Bioinformatics segment accounted for the largest market revenue share in 2023

Market Size & Forecast

  • Market Opportunities: USD 163.38 billion
  • Market Future Opportunities: USD 78.40 billion
  • CAGR : 13%
  • North America: Largest market in 2023

Market Summary

  • The market is a dynamic and evolving sector, driven by the growing prevalence of chronic diseases and the increasing adoption of advanced technologies such as artificial intelligence (AI) and machine learning (ML). According to a recent report, The market is expected to account for over 20% share of the total diagnostic market by 2025. The market's expansion is fueled by the rising demand for personalized treatment plans and the growing use of AI and ML in precision medicine.
  • However, data privacy and security concerns pose significant challenges, as the collection and analysis of vast amounts of patient data require robust security measures. Despite these challenges, the market presents numerous opportunities for growth, particularly in areas such as genomics, proteomics, and diagnostics. The ongoing development of regulatory frameworks and regional initiatives further underscores the market's continuous unfolding.

What will be the Size of the Precision Medicine Market during the forecast period?

Precision Medicine Market Size

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Precision Medicine Market Segmented and what are the key trends of market segmentation?

The precision medicine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

  • Application
    • Oncology
    • CNS
    • Respiratory
    • Immunology
    • Others
  • Technology
    • Bioinformatics
    • Gene sequencing
    • Drug discovery
    • Precision molecular diagnostic
    • Big data analytics
  • End-user
    • Pharmaceutical and biotechnology
    • Healthcare providers
    • Research and academic institutions
    • Diagnostic laboratories
  • Geography
    • North America
      • US
      • Canada
    • Europe
      • France
      • Germany
      • Italy
      • UK
    • APAC
      • China
      • India
      • Japan
    • South America
      • Brazil
    • Rest of World (ROW)

    By Application Insights

    The oncology segment is estimated to witness significant growth during the forecast period.

    In the realm of oncology, precision medicine has emerged as a transformative force, enabling healthcare professionals to create customized cancer treatment plans based on a patient's unique genetic and biomarker profiles. This approach allows for the identification of high-risk individuals, early cancer detection, precise cancer typing, and the selection of optimal treatment options. One application of precision medicine is molecularly targeted therapies, which are designed to inhibit specific molecular pathways driving cancer. Moreover, computational biology, epigenetic modifications, and genomic sequencing play pivotal roles in precision oncology. These technologies facilitate the discovery of biomarkers and the integration of multi-omics data, leading to a more comprehensive understanding of cancer development and progression.

    Furthermore, drug repurposing, protein profiling, and artificial intelligence are essential tools in the development of personalized medicine. Drug development in precision medicine relies heavily on patient stratification, clinical trial design, and data analytics. By utilizing these techniques, researchers can ensure that clinical trials are more effective and that treatments are tailored to specific disease subtypes. Additionally, next-generation sequencing, single-cell analysis, and CRISPR technology contribute to the ongoing evolution of precision medicine. According to recent studies, precision oncology is experiencing significant growth, with approximately 30% of oncology practices adopting this approach. Furthermore, industry experts anticipate that over 70% of oncology practices will integrate precision medicine into their treatment plans within the next five years.

    This trend underscores the increasing importance of precision medicine in the field of oncology and its potential to revolutionize cancer care.

    Precision Medicine Market Size

    Request Free Sample

    The Oncology segment was valued at USD 24.20 billion in 2019 and showed a gradual increase during the forecast period.

    Precision Medicine Market Size

    Request Free Sample

    Regional Analysis

    North America is estimated to contribute 41% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

    Precision Medicine Market Share by Geography

    See How Precision Medicine Market Demand is Rising in North America Request Free Sample

    In North America, the market is experiencing significant growth, fueled by substantial healthcare expenditures, advanced healthcare infrastructure, and a strong emphasis on research and development. The region's market expansion is anticipated to persist, driven by technological advancements, the increasing demand for personalized medicine, and the rising prevalence of chronic diseases. For instance, Roche and Janssen Biotech, Inc. Recently strengthened their collaboration to advance personalized healthcare through the development of companion diagnostics, utilizing Roche's cobas diagnostic platforms to identify patients most likely to benefit from Janssen's targeted cancer therapies.

    This strategic partnership underscores the market's ongoing evolution and the potential for continued growth. The market in North America is expected to witness notable activity and innovation during the forecast period.

    Market Dynamics

    Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

    The market is experiencing significant growth as the healthcare industry shifts towards personalized treatment approaches. This market encompasses various elements, including clinical trial recruitment strategies, predictive biomarkers in oncology, genomic data interpretation methods, development of targeted therapies, and the impact of pharmacogenomics on drug safety. One key area of focus is the application of artificial intelligence in diagnostics, which is transforming the way diseases are identified and treated. Integration of multi-omics data for precision medicine is also gaining momentum, enabling the identification of novel cancer biomarkers and improving diagnostic accuracy of cancer detection. Moreover, the development of next-generation sequencing applications and improved diagnostic imaging techniques are revolutionizing the field, leading to better patient outcomes using predictive modeling.

    Strategies for reducing healthcare disparities and evaluating new precision medicine technologies are also critical components of this market. Cost-effectiveness analysis of precision medicine interventions and managing data privacy and security are essential considerations. In this regard, a significant portion of research efforts is devoted to ethical considerations in precision medicine research and the implementation of precision medicine in clinical practice. Adoption rates for precision medicine technologies vary significantly across different segments. For instance, more than 70% of new product developments focus on oncology applications, reflecting the high demand for personalized cancer treatments. However, the academic sector lags behind in adoption, accounting for a minority share of the market.

    In conclusion, the market is witnessing rapid growth as the industry embraces personalized treatment approaches. The integration of advanced technologies, a focus on improving patient outcomes, and the development of next-generation sequencing applications are driving market expansion.

    Precision Medicine Market Size

    What are the key market drivers leading to the rise in the adoption of Precision Medicine Industry?

    • The increasing prevalence of chronic diseases serves as the primary market driver, as an escalating number of individuals are diagnosed with conditions such as diabetes, cancer, and cardiovascular diseases, necessitating continuous demand for healthcare solutions and treatments. 

    • Chronic diseases, including diabetes, cardiovascular disease, cancer, respiratory diseases, and neurological disorders, represent a significant challenge for healthcare systems worldwide. The prevalence of these conditions is on the rise, driven by factors such as an aging population and lifestyle changes. According to the World Health Organization (WHO), the global population aged 60 and above is projected to double by 2050. Moreover, unhealthy habits, such as physical inactivity, poor diet, and tobacco use, contribute to the increasing prevalence of chronic diseases. The demand for precision medicine, which tailors treatment to individual patients based on their genetic makeup and lifestyle factors, is growing in response to this trend.
    • Precision medicine offers the potential for more effective and personalized treatment approaches, which can lead to better health outcomes and reduced healthcare costs. This evolving landscape presents opportunities for various sectors, including pharmaceuticals, diagnostics, and technology companies, to develop innovative solutions that cater to the unique needs of chronic disease patients. In conclusion, the continuous rise in chronic diseases and the growing demand for personalized treatment options create a dynamic market that is undergoing significant transformation. The aging population and lifestyle changes are key drivers of this trend, making it essential for businesses to stay informed and adapt to the evolving needs of this market.
    • By leveraging the latest research and insights, companies can develop innovative solutions that cater to the unique requirements of chronic disease patients and contribute to better health outcomes.

    What are the market trends shaping the Precision Medicine Industry?

    • The increasing adoption of artificial intelligence (AI) and machine learning (ML) in precision medicine represents a significant market trend. This technological advancement is transforming the healthcare industry.

    • The integration of Artificial Intelligence (AI) and Machine Learning (ML) in precision medicine is a significant trend transforming the industry. These technologies facilitate the analysis of extensive patient data, leading to more targeted and customized treatments. In the realm of precision medicine, AI and ML contribute to two primary synergies: risk prediction and therapy planning. Diagnosis: The integration of AI/ML algorithms with precision medicine addresses the most complex challenges in personalized healthcare. By analyzing patient data, these technologies assist clinicians, doctors, and researchers in making informed decisions, enhancing patient care. Drug discovery: AI and ML expedite the drug discovery process by identifying potential drug targets and predicting new drugs' efficacy.
    • This innovation reduces the time and resources required to bring new treatments to market. The synergy between AI/ML and precision medicine is continuously evolving, with new applications emerging across various sectors. This data-driven approach offers numerous advantages, including improved patient outcomes and cost savings. By harnessing the power of AI and ML, the precision medicine industry is revolutionizing healthcare, making it more accessible and effective for individuals worldwide.

    What challenges does the Precision Medicine Industry face during its growth?

    • The integration of precision medicine in the healthcare industry presents a significant challenge due to the complex data privacy and security concerns associated with handling sensitive patient information. Ensuring the confidentiality, integrity, and availability of such data is essential for industry growth and maintaining public trust. 

    • The market faces a significant challenge in ensuring data privacy and security. With the increasing collection and analysis of sensitive patient data, including genetic and molecular information, medical history, and lifestyle factors, the risk of data breaches and unauthorized access becomes a major concern. According to a recent study, the healthcare industry experienced over 41 million records breached in 2020 alone. Precision medicine data is particularly valuable and attractive to cybercriminals due to its potential for financial gain and the potential for identity theft and insurance fraud. To mitigate these risks, precision medicine researchers and healthcare providers must prioritize data security.
    • Implementing encryption, firewalls, and other security technologies is essential for protecting patient data during storage and transmission. Regularly updating software and conducting security audits can also help identify vulnerabilities and prevent potential attacks. Additionally, strict access controls and employee training programs can help ensure that only authorized individuals have access to sensitive data. Despite these challenges, the market continues to evolve, with new technologies and innovations emerging to improve patient care and outcomes. As the market grows and matures, addressing data privacy and security concerns will remain a critical priority for stakeholders.

    Exclusive Customer Landscape

    The precision medicine market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the precision medicine market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

    Precision Medicine Market Share by Geography

     Customer Landscape of Precision Medicine Industry

    Competitive Landscape & Market Insights

    Companies are implementing various strategies, such as strategic alliances, precision medicine market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

    AbbVie Inc. - This company specializes in developing customized medicines with pinpoint accuracy for diverse treatment areas. Through advanced research and technology, they deliver personalized healthcare solutions.

    The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Biocrates Life Sciences AG
    • Bristol Myers Squibb Co.
    • Catalent Inc.
    • Eli Lilly and Co.
    • F. Hoffmann La Roche Ltd.
    • Gilead Sciences Inc.
    • IQVIA Holdings Inc.
    • Johnson and Johnson Services Inc.
    • Lonza Group Ltd.
    • Merck and Co. Inc.
    • Novartis AG
    • Parexel International Corp.
    • Pfizer Inc.
    • QIAGEN N.V.
    • Sanofi SA
    • Takeda Pharmaceutical Co. Ltd.
    • Thermo Fisher Scientific Inc.

    Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

    Recent Development and News in Precision Medicine Market

    • In January 2024, Merck KGaA and Pfizer Inc. Announced a strategic collaboration to co-develop and commercialize oncology therapies based on Merck KGaA's precision medicine platform, which includes the biomarker Selumetinib (RECIST-1). This partnership is expected to accelerate the development of personalized treatment options for cancer patients (Merck KGaA Press Release, 2024).
    • In March 2024, Illumina Inc. Launched the TruSight OncoSeq Comprehensive Cancer Panel v3, a next-generation sequencing (NGS) assay designed to detect over 400 cancer-associated genes. This advancement in genomic testing enables more comprehensive and accurate cancer diagnosis and treatment planning (Illumina Inc. Press Release, 2024).
    • In May 2024, the US Food and Drug Administration (FDA) granted approval for Guardant Health's Lunar-2 liquid biopsy test, which can detect and monitor tumor DNA in blood samples. This non-invasive test is designed to help physicians make informed treatment decisions for patients with advanced, metastatic, or recurrent solid tumors (FDA Press Release, 2024).
    • In April 2025, Roche Holding AG completed the acquisition of Foundation Medicine Inc., a leading precision medicine company specializing in comprehensive genomic profiling. This strategic move expands Roche's diagnostic offerings and strengthens its position in the precision oncology market (Roche Holding AG Press Release, 2025).

    Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Precision Medicine Market insights. See full methodology.

    Market Scope

    Report Coverage

    Details

    Page number

    222

    Base year

    2024

    Historic period

    2019-2023

    Forecast period

    2025-2029

    Growth momentum & CAGR

    Accelerate at a CAGR of 13%

    Market growth 2025-2029

    USD 78.4 billion

    Market structure

    Fragmented

    YoY growth 2024-2025(%)

    11.3

    Key countries

    US, Germany, Canada, China, UK, Japan, France, Brazil, India, and Italy

    Competitive landscape

    Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

    Request Free Sample

    Research Analyst Overview

    • In the rapidly evolving landscape of healthcare, precision medicine is emerging as a game-changer, reshaping the way treatments are developed and administered. This approach, which leverages therapeutic efficacy insights based on genetic variation and individual patient characteristics, is revolutionizing targeted therapy in various disease areas. Precision oncology, a significant segment of this market, is witnessing a surge in activity, driven by advancements in computational biology and epigenetic modifications. Artificial intelligence (AI) is playing a pivotal role in drug development by enabling treatment response prediction and accelerating the discovery of new therapeutic targets. Molecular diagnostics and proteomic profiling are essential tools in precision medicine, facilitating the identification of biomarkers and enabling personalized treatment plans.
    • The integration of multi-omics data, including genomic sequencing and big data analytics, is paving the way for more accurate patient stratification and clinical trial design. Innovations such as CRISPR technology, liquid biopsy, single-cell analysis, and diagnostic imaging are further expanding the market's reach and potential. These technologies enable the detection and monitoring of disease subtypes and facilitate the development of cell therapies and next-generation sequencing techniques. Machine learning algorithms are being employed to analyze vast amounts of data, uncovering new insights and enabling the repurposing of existing drugs. The integration of AI and data analytics in drug development is leading to more efficient and cost-effective processes, ultimately benefiting patients.
    • The market's dynamics are continuously unfolding, with new technologies and applications emerging regularly. This market's evolution underscores the importance of staying informed and adaptive in the ever-changing healthcare landscape.

    What are the Key Data Covered in this Precision Medicine Market Research and Growth Report?

    • What is the expected growth of the Precision Medicine Market between 2025 and 2029?

      • USD 78.4 billion, at a CAGR of 13%

    • What segmentation does the market report cover?

      • The report segmented by Application (Oncology, CNS, Respiratory, Immunology, and Others), Technology (Bioinformatics, Gene sequencing, Drug discovery, Precision molecular diagnostic, and Big data analytics), End-user (Pharmaceutical and biotechnology, Healthcare providers, Research and academic institutions, and Diagnostic laboratories), and Geography (North America, Europe, Asia, and Rest of World (ROW))

    • Which regions are analyzed in the report?

      • North America, Europe, Asia, and Rest of World (ROW)

    • What are the key growth drivers and market challenges?

      • Growing prevalence of chronic diseases, Data privacy and security issues associated with precision medicine

    • Who are the major players in the Precision Medicine Market?

      • Key Companies AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocrates Life Sciences AG, Bristol Myers Squibb Co., Catalent Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., IQVIA Holdings Inc., Johnson and Johnson Services Inc., Lonza Group Ltd., Merck and Co. Inc., Novartis AG, Parexel International Corp., Pfizer Inc., QIAGEN N.V., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Thermo Fisher Scientific Inc.

    Market Research Insights

    • The market encompasses a range of innovative technologies and approaches aimed at optimizing treatment, enhancing patient engagement, and improving disease management through personalized healthcare solutions. According to recent estimates, The market is projected to reach USD158.8 billion by 2025, representing a compound annual growth rate of 16.6% between 2020 and 2025. This growth is driven by the increasing prevalence of minimal residual disease, the rising demand for companion diagnostics, and the integration of data from various sources to inform clinical decision-making. In contrast, the market for traditional diagnostic methods is projected to grow at a much slower pace, reaching only USD105.6 billion by 2025.
    • Precision medicine's ability to provide early detection, account for drug interactions, and enable remote monitoring, among other benefits, sets it apart from conventional diagnostic methods. However, challenges such as tumor heterogeneity, regulatory compliance, and data security remain significant hurdles to market expansion. Despite these challenges, the potential for improved patient outcomes and reduced healthcare costs continues to fuel the market's growth.

    We can help! Our analysts can customize this precision medicine market research report to meet your requirements.

    Get in touch

    Table of Contents not available.

    Research Methodology

    Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

    INFORMATION SOURCES

    Primary sources

    • Manufacturers and suppliers
    • Channel partners
    • Industry experts
    • Strategic decision makers

    Secondary sources

    • Industry journals and periodicals
    • Government data
    • Financial reports of key industry players
    • Historical data
    • Press releases

    DATA ANALYSIS

    Data Synthesis

    • Collation of data
    • Estimation of key figures
    • Analysis of derived insights

    Data Validation

    • Triangulation with data models
    • Reference against proprietary databases
    • Corroboration with industry experts

    REPORT WRITING

    Qualitative

    • Market drivers
    • Market challenges
    • Market trends
    • Five forces analysis

    Quantitative

    • Market size and forecast
    • Market segmentation
    • Geographical insights
    • Competitive landscape

    Interested in this report?

    Get your sample now to see our research methodology and insights!

    Download Now

    Frequently Asked Questions

    Precision Medicine market growth will increase by $ 78.4 bn during 2025-2029.

    The Precision Medicine market is expected to grow at a CAGR of 13% during 2025-2029.

    Precision Medicine market is segmented by Application( Oncology, CNS, Respiratory, Immunology, Others) Technology( Bioinformatics, Gene sequencing, Drug discovery, Precision molecular diagnostic, Big data analytics) End-user( Pharmaceutical and biotechnology, Healthcare providers, Research and academic institutions, Diagnostic laboratories)

    AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocrates Life Sciences AG, Bristol Myers Squibb Co., Catalent Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., IQVIA Holdings Inc., Johnson and Johnson Services Inc., Lonza Group Ltd., Merck and Co. Inc., Novartis AG, Parexel International Corp., Pfizer Inc., QIAGEN N.V., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc. are a few of the key vendors in the Precision Medicine market.

    North America will register the highest growth rate of 41% among the other regions. Therefore, the Precision Medicine market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

    US, Germany, Canada, China, UK, Japan, France, Brazil, India, Italy

    • Growing prevalence of chronic diseasesChronic diseases are long-term health conditions that require medical attention and management. These include conditions such as diabetes is the driving factor this market.
    • cardiovascular disease is the driving factor this market.
    • cancer is the driving factor this market.
    • respiratory diseases is the driving factor this market.
    • and neurological disorders. The prevalence of chronic diseases is increasing globally is the driving factor this market.
    • and this trend is driving the demand for precision medicine. One of the factors driving the prevalence of chronic diseases is the aging population. For instance is the driving factor this market.
    • according to the World Health Organization (WHO) is the driving factor this market.
    • by 2050 is the driving factor this market.
    • the worlds population of people aged 60 years and above will double (2.1 billion). Additionally is the driving factor this market.
    • changes in lifestyle and behavior is the driving factor this market.
    • such as physical inactivity is the driving factor this market.
    • poor diet is the driving factor this market.
    • and tobacco use is the driving factor this market.
    • are contributing to the rise in the prevalence of chronic diseases. The traditional approach to treating chronic diseases has been a one-size-fits-all approach that relies on standardized treatments and medications. However is the driving factor this market.
    • this approach is not always effective for all patients. Precision medicine offers a more personalized approach to treatment that can be tailored to the individual patients genetic and biological characteristics. Precision medicine enables healthcare providers to identify genetic and protein-based biomarkers that are associated with specific diseases. This allows for the development of targeted therapies that can be more effective and have fewer side effects than traditional treatments. In addition is the driving factor this market.
    • precision medicine can help identify individuals who are at increased risk of developing certain chronic diseases is the driving factor this market.
    • allowing for earlier intervention and prevention. Thus is the driving factor this market.
    • the growing prevalence of chronic diseases is one of the major drivers which is expected to drive the growth of the global precision medicine market during the forecast period. is the driving factor this market.

    The Precision Medicine market vendors should focus on grabbing business opportunities from the Oncology segment as it accounted for the largest market share in the base year.